FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available

Am J Health Syst Pharm. 2005 Apr 1;62(7):668-72. doi: 10.1093/ajhp/62.7.668.
No abstract available

Publication types

  • News

MeSH terms

  • Advisory Committees / legislation & jurisprudence
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Clinical Trials as Topic / legislation & jurisprudence
  • Cyclooxygenase Inhibitors / adverse effects*
  • Drug Industry / legislation & jurisprudence
  • Drug Labeling / legislation & jurisprudence
  • Humans
  • United States
  • United States Food and Drug Administration*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors